癌症研究
表皮生长因子受体
腺癌
蛋白激酶B
PI3K/AKT/mTOR通路
生物
PTEN公司
肺癌
ERBB3型
信号转导
医学
表皮生长因子受体抑制剂
细胞生长
福克斯M1
恶性转化
奥西默替尼
埃罗替尼
靶向治疗
鳞癌
视网膜母细胞瘤
体内
视网膜母细胞瘤蛋白
表皮生长因子
癌
肺
细胞
克拉斯
细胞周期
癌症
病理
转录因子
吉非替尼
作者
Alexandria Dymun,Mark Yungjie Jeng,Arielle Elkrief,Harshita Mehrotra,Soo‐Ryum Yang,Christina E. Wilson,Natasha Rekhtman,Irina Linkov,Amanda Pupo,Christina J. Falcon,Clare Wilhelm,Parvathy Manoj,钟竑,Harsha Sridhar,Mark G. Kris,Nicholas D. Socci,Juan Qiu,Elisa de Stanchina,Allison L. Richards,Mark T.A. Donoghue
标识
DOI:10.1126/scitranslmed.aea4881
摘要
Histologic transformation to lung squamous cell carcinoma (LUSC) is an underrecognized mechanism of resistance in epidermal growth factor receptor ( EGFR )–mutant lung adenocarcinoma (LUAD). Although AKT and MYC activation have been linked to LUSC features, the clinicogenomic determinants of this transformation remain undefined. In this study, we performed comprehensive clinical and multiomic profiling—including genomic, transcriptomic, methylation, and proteomic analyses—of EGFR -mutant tumors that were transforming, adenosquamous (LUAS), or de novo LUSC. Patients with EGFR -mutant LUSC or LUAS had shorter overall survival on first-line osimertinib compared with those with EGFR -mutant LUAD. Transforming tumors were enriched for alterations in the retinoblastoma (Rb) and AKT pathways, particularly cyclin-dependent kinase inhibitor 2A/B ( CDKN2A/B ) deletions. These alterations were also frequent in EGFR –wild-type LUSC and associated with shorter time-to-osimertinib discontinuation. In genetically engineered human in vivo models, Rb inactivation, in combination with AKT and MYC activation, enhanced the acquisition of LUSC features. Single-cell RNA profiling of such models recapitulated the molecular changes observed in the transforming clinical specimens and identified MET pathway up-regulation during transformation. Combined EGFR and MET inhibition suppressed tumor growth in patient-derived xenograft models of LUSC transformation. Together, these findings highlight Rb pathway inactivation as a promoter of LUSC transformation in EGFR -mutant lung cancer and identify MET signaling as a therapeutic vulnerability that may suppress plasticity in this setting and extend response to targeted therapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI